| 1. |
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human
homologue. Nature 372:425–432
|
| |
| 2. |
Langin D, Lafontan, M (2000) Millennium fat-cell lipolysis reveals unsuspected novel tracks. Horm Metab Res 32:443–452
|
| |
| 3. |
Trayhurn P, Beattie JH (2001) Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ.
Proc Nutr Soc 60:329–339
|
| |
| 4. |
Frühbeck G, Gómez-Ambrosi J, Muruzábal FJ, Burrell MA (2001) The adipocyte: a model for integration of endocrine and metabolic
signaling in energy metabolism regulation. Am J Physiol 280:E827–E847
|
| |
| 5. |
Frühbeck G, Gómez-Ambrosi J (2001) Rationale for the existence of additional adipostatic hormones. FASEB J 15:1996–2006
|
| |
| 6. |
Frühbeck G (2001) A heliocentric view of leptin. Proc Nutr Soc 60:301–318
|
| |
| 7. |
Marette A (2002) Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr Opin Clin
Nutr Metab Care 5:377–383
|
| |
| 8. |
Blake GJ, Ridker PM (2002) Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 252:283–294
|
| |
| 9. |
Frühbeck G, Gómez-Ambrosi J (2003) Control of body weight: a physiologic and transgenic perspective. Diabetologia 46:143–172
|
| |
| 10. |
Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347–355
|
| |
| 11. |
Frühbeck G (2004) The adipose tissue as a source of vasoactive factors. Curr Med Chem (Cardiovasc Hematol Agents) 2:197–208
|
| |
| 12. |
La Cava A, Alviggi C, Matarese G (2004) Unravelling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med
82:4–11
|
| |
| 13. |
Granger JP (2004) Inflammatory cytokines, vascular function, and hypertension. Am J Physiol Reg Integr Comp Physiol 286:R989–R990
|
| |
| 14. |
Gimeno RE, Klaman LD (2005) Adipose tissue as an active endocrine organ: recent advances. Curr Opin Pharmacol 5:122–128
|
| |
| 15. |
Hutley L, Prins JB (2005) Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci 330:280–289
|
| |
| 16. |
Trayhurn, P (2005) Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand 184:285–293
|
| |
| 17. |
Yu Y-H, Ginsberg HN (2005) Adipocyte signaling and lipid homeostasis. Sequelae of insulin-resistant adipose tissue. Circ Res
96:1042–1052
|
| |
| 18. |
Bell CG, Walley AJ, Froguel P (2005) The genetics of human obesity. Nat Rev Genet 6:221–234
|
| |
| 19. |
Berg AH, Scherer PE (2005) Adipose tissue, inflamation and cardiovascular disease. Circ Res 96:939–949
|
| |
| 20. |
Lau DCW, Dhillon B, Yan H, Szmitko PE, Verma, S (2005) Adipokines: molecular links between obesity and atherosclerosis. Am
J Physiol Heart Circ Physiol 288:H2031–H2041
|
| |
| 21. |
Nawrocki AR, Scherer PE (2005) Adipose tissue, adipokines, and inflammation. Drug Discovery Today 10:1219–1230
|
| |
| 22. |
Fantuzzi G (2005) Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115:911–919
|
| |
| 23. |
Van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444:875–880
|
| |
| 24. |
Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846
|
| |
| 25. |
Fain JN (2006) Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and
primarily due to the nonfat cells. Vitam Horm 74:443–477
|
| |
| 26. |
Matsuzawa Y (2006) Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract
Cardiovasc Med 3:35–42
|
| |
| 27. |
Trayhurn P, Bing C, Wood IS (2006) Adipose tissue and adipokines—energy regulation from the human perspective. J Nutr 136:1935S–1939S
|
| |
| 28. |
Despres JP, Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444:881–887
|
| |
| 29. |
Abizaid A, Gao Q, Horvath TL (2006) Thoughts for food: brain mechanisms and peripheral energy balance. Neuron 51:691–702
|
| |
| 30. |
Pond CM (1999) Physiological specialisation of adipose tissue. Prog Lipid Res 38:225–248
|
| |
| 31. |
Spiegelman BM, Hotamisligil GS, Graves RA, Tontonoz P (1993) Regulation of adipocyte gene expression and syndromes of obesity/diabetes.
J Biol Chem 268:68236–6826
|
| |
| 32. |
Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM (2000) Transcriptional regulation of adipogenesis. Genes Dev 14:1293–1307
|
| |
| 33. |
Gregoire FM (2001) Adipocyte differentiation: from fibroblast to endocrine cell. Exp Biol Med 226:997–1002
|
| |
| 34. |
Rosen ED, MacDougald OA (2006) Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 7:885–896
|
| |
| 35. |
Unger RH (2003) The physiology of cellular liporegulation. Annu Rev Physiol 65:333–347
|
| |
| 36. |
Shen W, Wang Z, Punyanita M, Lei J, Sinav A, Kral JG, Imielinska C, Ross R, Heymsfield SB (2003) Adipose quantification by
imaging methods: a proposed classification. Obesity Res 11:5–16
|
| |
| 37. |
Cannon B, Nedergaard, J (2004) Brown adipose tissue: function and physiological significance. Physiol Rev 84:277–359
|
| |
| 38. |
Wajchenberg BL (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Rev 21:697–738
|
| |
| 39. |
Lafontan M, Berlan M (2003) Do regional differences in adipocyte biology provide new patho-physiological insights? Trends
Pharmacol Sci 24:276–283
|
| |
| 40. |
Fried SK, Ross RR (2004) Biology of visceral adipose tissue. In: Bray GA, Bouchard C (eds) Handbook of obesity. Etiology and
pathophysiology, 2nd edn. Marcel Dekker, Inc., New York, pp 589–614
|
| |
| 41. |
Gómez-Ambrosi J, Catalán V, Diez-Caballero A, Martínez-Cruz A, Gil MJ, García-Foncillas J, Cienfuegos JA, Salvador J, Mato
JM, Frühbeck G (2004) Gene expression profile of omental adipose tissue in human obesity. FASEB J 18:215–217
|
| |
| 42. |
Linder K, Arner P, Flores-Morales A, Tollet-Egnell P, Norstedt G (2004) Differentially expressed genes in visceral and subcutaneous
adipose tissue of obese men and women. Prog Lipid Res 45:148–154
|
| |
| 43. |
Schäffler A, Schölmerich J, Buechler C (2006) The role of ‘adipotropins’ and the clinical importance of a potential hypothalamic-pituitary-adipose
axis. Nat Clin Pract Endocrinol Metab 2:374–383
|
| |
| 44. |
Jump DB (2004) Fatty acid regulation of gene transcription. Crit Rev Clin Lab Sci 41:41–78
|
| |
| 45. |
Cousin B, Munoz O, Andre M, Fontanilles AM, Dani C, Cousin JL, et al (1999) A role for preadipocytes as macrophage-like cells.
FASEB J 13:305–312
|
| |
| 46. |
Peeraully MR, Jenkins JR, Trayhurn P (2004) NGF gene expression and secretion in white adipose tissue: regulation in 3T3-L1
adipocytes by hormones and inflammatory cytokines. Am J Physiol Endocrinol Metab 287:E331–E339
|
| |
| 47. |
Wang B, Jenkins JR, Trayhurn, P (2005) Expression and secretion of inflammation-related adipokines by human adipocytes differentiated
in culture: integrated response to TNF-α. Am J Physiol Endocrinol Metab 288:E731–E740
|
| |
| 48. |
Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA (2004) An inflammatory cascade leading to hyper-resistinemia
in humans. PloS Med 1:161–168
|
| |
| 49. |
Frühbeck G (2006) Vasoactive factors and inflammatory mediators produced in adipose tissue. In: Fantuzzi G, Mazzone T (eds)
Health and nutrition. Adipose tissue and adipokines in health and disease. Humana Press Inc., Totowa, NJ, pp 61–75
|
| |
| 50. |
Chaldakov GN, Tonchev AB, Tuncel N, Atanassova P, Aloe L. Adipose tissue and mast cells. Adipokines as yin-yang modulators
of inflammation. In: Fantuzzi G, Mazzone T, (eds) Health and nutrition. Adipose tissue and adipokines in health and disease.
Humana Press Inc., Totowa, NJ, pp 147–154
|
| |
| 51. |
Murdolo G, Smith U (2006) The dysregulated adipose tissue: a connecting link between insulin resistance, type 2 diabetes mellitus
and atherosclerosis. Nutr Metab Cardiovasc Dis 16:S35–S38
|
| |
| 52. |
Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1793–1801
|
| |
| 53. |
Wenger RH (2002) Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors,
and O2-regulated gene expression. FASEB J 16:1151–1162
|
| |
| 54. |
Fearnly GR, Vincent CT, Chakrabarti R (1959) Reduction of blood fibrinolytic activity in diabetes mellitus by insulin. Lancet
2:1067
|
| |
| 55. |
Ogston D, McAndrew GM (1964) Fibrinolysis in obesity. Lancet 14:1205–1207
|
| |
| 56. |
Grace CS, Goldrick RB (1968) Fibrinolysis.and body build. Interrelationships between blood fibrinolysis, body composition
and parameters of lipid and carbohydrate metabolism. J Atheroscler Res 8:705–719
|
| |
| 57. |
Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al (1999) Markers of inflammation and prediction
of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353:1649–1652
|
| |
| 58. |
Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, et al (2001) The relation of markers of inflammation
to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 50:2384–2389
|
| |
| 59. |
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type
2 diabetes mellitus. JAMA 286:327–334
|
| |
| 60. |
Festa A, D'Agostino R Jr., Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1
predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131–1137
|
| |
| 61. |
Freeman DJ, Norrie J, Caslake, MJ, Gaw A, Ford I, Lowe GD, et al (2002) C-reactive protein is an independent predictor of
risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596–1600
|
| |
| 62. |
Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, et al (2005) Intensive lifestyle intervention or metformin
on inflammation and coagulation in participants with impaired fasting glucose tolerance. Diabetes 54:1566–1572
|
| |
| 63. |
Linton MF, Fazio S (2003) Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord 27(Suppl 3):S35–S40
|
| |
| 64. |
Castrillo A, Tontonoz P (2004) Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation.
Annu Rev Cell Dev Biol 20:455–480
|
| |
| 65. |
Clément K, Viguerie N, Poitou C, Carette C, Peñoux V, Curat CA, et al (2004) Weight loss regulates inflammation-related genes
in white adipose tissue of obese subjects. FASEB J 18:1657–1669
|
| |
| 66. |
Poitou C, Viguerie N, Cancello R, De Matteis R, Cinti S, Stich, V. et al (2005) Serum amyloid A: production by human white
adipocyte and regulation by obesity and nutrition. Diabetologia 48:519–528
|
| |
| 67. |
Charo IF, Taubman MB (2004) Chemokines in the pathogenesis of vascular disease. Circ Res 95:858–866
|
| |
| 68. |
Malavazos AE, Cereda E, Morricone L, Coman C, Corsi MM, Ambrosi B (2005) Monocyte chemoattractant protein 1: a possible link
between visceral adipose tissue-associated inflammation and subclinical echocardiographic abnormalities in uncomplicated obesity.
Eur J Endocrinol 153:871–877
|
| |
| 69. |
Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al (2005) Visfatin: a protein secreted by visceral
fat that mimics the effects of insulin. Science 307:426–430
|
| |
| 70. |
Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al (2005) Plasma visfatin concentrations and fat depot-specific
mRNA expression in humans. Diabetes 54:2911–2916
|
| |
| 71. |
Yang Q, Graham TE., Mody N, Preitner F, Peroni OD., Zabolotny JM, et al (2005) Serum retinol binding protein 4 contributes
to insulin resistance and type 2 diabetes. Nature 436:356–362
|
| |
| 72. |
Cancello R, Clement, K (2006) Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration
in human white adipose tissue. BJOG 113:1141–1147
|
| |
| 73. |
Arner P (2006) Visfatin—a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab 91:28–30
|
| |
| 74. |
Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al (2006) Retinol-binding protein 4 and insulin resistance
in lean, obese, and diabetic subjects. N Engl J Med 354:2552–2563
|
| |
| 75. |
Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, et al (2006) Plasma retinol-binding protein-4 concentrations are elevated
in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 29:2457–2461
|
| |
| 76. |
Janke J, Engeli S, Boschmann M, Adams F, Bohnke J, Luft FC, et al (2006) Retinol-binding protein 4 in human obesity. Diabetes
55:2805–2810
|
| |
| 77. |
Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance.
J Clin Invest 116:3015–3025
|
| |
| 78. |
Song MJ, Kim KH., Yoon JM, Kim JB (2006) Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes.
Biochem Biophys Res Commun 346:739–745
|
| |
| 79. |
Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860–867
|
| |
| 80. |
Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6:772–783
|
| |
| 81. |
Lumeng CN, Bodzin JL, Saltiel AR (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin
Invest 117:175–184
|
| |
| 82. |
Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR (2007) Increased inflammatory properties of adipose tissue macrophages recruited
during diet-induced obesity. Diabetes 56:16–23
|
| |
| 83. |
Choudhury J, Sanyal AJ (2004) Clinical aspects of fatty liver disease. Semin Liver Dis 24:349–362
|
| |
| 84. |
Roden M (2006) Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nat Clin Pract
Endocrinol Metab 2:335–348
|
| |
| 85. |
Tilg H, Hotamisligil GS (2006) Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance.
Gastroenterology 131:934–945
|
| |
| 86. |
Utzschneider KM, Kahn SE (2006) The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab
91:4753–4761
|
| |